|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Although ApoCIII transgenic mice have been generated as an animal model for the study of hypertriglyceridemia, the features of lipoprotein metabolism in mice differ greatly from those in humans.
|
22023023 |
2012 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We sequenced APOC3 3'UTR in 100 type 2 diabetic (TD2) patients with severe HTG (TG > 15 mmol/L) (HTG group) compared to 100 normotriglyceridemic patients (NTG group).
|
27794214 |
2016 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Apolipoprotein C3 (apoC3) is associated with hypertriglyceridemia and is therefore closely related to CHD.
|
30511426 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RRFs were obtained by ethanol extraction from Rosa rugosa Thunb.. Transgenic mice expressing human Apolipoprotein C3 (ApoC3) were used as a mouse model of hypertriglyceridemia.
|
31100436 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The agent blocks the function of the mRNA of apolipoprotein C3 and successfully treats severe hypertriglyceridaemia in phase 3 trials (Ionis Pharmaceuticals).
|
28441154 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We first used the human Apolipoprotein CIII transgenic (Tg-ApoCIII) mice and non-transgenic (Non-Tg) littermates to examine the effect of HTG on stroke.
|
26970521 |
2016 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Elevated apolipoprotein C-III (apoC-III) levels are associated with hypertriglyceridaemia and coronary heart disease.
|
31329855 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Thus, irrespective of receptor-mediated remnant clearance by the liver, liver-specific expression of human apoCI causes hypertriglyceridemia in the absence of the VLDLr and apoCIII.
|
16478678 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
We assessed the effects on these complexes of placebo or 100-300 mg volanesorsen, a generation 2.0+ antisense drug that targets apoC3 mRNA in patients with hypertriglyceridemia, including familial chylomicronemia syndrome (n = 3), volanesorsen monotherapy (n = 51), and as add-on to fibrate (n = 26), treated for 85 days and followed for 176 days.
|
26848137 |
2016 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
LHGDN |
Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia.
|
16861622 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The underlying mechanism may be improved glycaemic control, which leads to reduced expression of apoCIII, a key regulator of hypertriglyceridaemia in hyperglycaemic patients.
|
30073766 |
2019 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice.
|
2167514 |
1990 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
PCSK9 significantly conferred prediction of both hypercholesterolemia and combined hyperlipidemia at a level of 235 ng/ml; apoC3 levels for hypertriglyceridemia, hypercholesterolemia and combined hyperlipidemia were 80.0, 71.5, and 86.4 μg/ml, respectively; and sdLDL-C for hypertriglyceridemia, hypercholesterolemia, combined hyperlipidemia and hypo high density lipoprotein (HDL) cholesterolemia 3.5, 2.5, 4.5, and 2.5 mg/dl, respectively (all p<0.001 for area under the receiver-operating characteristic curve).
|
27713142 |
2017 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The less common allele (S2) of the SstI polymorphism on the 3' untranslated region of the APOC3 gene has been previously associated with increased triglycerides, total cholesterol (TC), and apoCIII levels and cardiovascular risk on several, but not all, studies.
|
11500189 |
2001 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
LHGDN |
Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism.
|
16495512 |
2006 |
|
Hypertriglyceridemia
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Variation in the expression of apoC-III has been credibly documented to have an important role in hypertriglyceridemia.
|
11353333 |
2001 |